all report title image

XEROSTOMIA THERAPEUTICS MARKET ANALYSIS

Xerostomia Therapeutics Market, by Product Type (Salivary Stimulants, Salivary Substitutes, Salivary Pen, Dentifrices, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Oct 2024
  • Code : CMI4471
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Xerostomia Therapeutics MarketSize and Trends

Global Xerostomia Therapeutics Market: Dynamics

The major drivers of xerostomia therapeutics market include rising geriatric population and increasing incidence of medical conditions such as Sjögren disease, hypertension, Parkinson’s disease, cancer, HIV, diabetes, and others. For instance, the American College of Rheumatology reported that around 3.1 million people suffered from Sjogren's disorder in the U.S. in 2019. Moreover, the use of treatments such as chemotherapy and radiography for head or neck cancer treatment is expected to drive growth of xerostomia therapeutic market over the forecast period. Chemotherapy leads to damage of salivary gland cells and makes saliva thicker. However, this is a temporary side effect, which lasts for two-eight weeks post therapy. Radiotherapy related xerostomia lasts up to atleast six months post therapy. For instance, internal radiotherapy, external radiotherapy and systemic radiotherapy are widely used treatment methods for head and neck cancer.

Medicinal products such as toothpaste, mouthwash, lozenges, saliva substitute gels, and sugar-free chewing gums are easily available and inexpensive, hence driving the growth of the market. Furthermore, some expensive drugs such as Salagen, which are used as salivary stimulants for xerostomia treatment have favorable reimbursement policies. For instance, Ontario Ministry of Health and Long-Term Care provides funds to patients with radiation-induced xerostomia undergoing treatment with drug, Salagen, under the Exceptional Access Program (EAP). Furthermore, prescribed medicines such as antiparkinsonian, sedatives, antidepressants, and others cause xerostomia and its increasing usage is expected to drive the market growth. For instance, the National Institute of Dental and Craniofacial Research states that over 400 medications may cause xerostomia.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.